59results about How to "Growth inhibitory activity" patented technology

The invention relates to a benzimidazole zinc complex and a preparation method thereof. A chemical name of the benzimidazole zinc complex is dichloro-2-(2-(1H-benzimidazole-2-)benzyl)-1H-benzimidazole zinc complex. The preparation method includes following steps: mixing 2-(carboxymethyl)benzoic acid with o-phenylenediamine, placing the mixture in phosphoric acid, performing a heating process at 180 DEG C for 3 hours to obtain a purple-green reactant, cooling the reactant to room temperature, adding distilled water, performing a neutralization reaction to obtain a yellow-green solid, performing a washing process through distilled water for three times, carrying out a filtering process, carrying out a recrystallization process through alcohol to obtain a yellow-green solid 2-(2-(1H-benzimidazole-2-)benzyl)-1H-benzimidazole, namely a ligand, dissolving ZnCl2 and the ligand 2-(2-(1H-benzimidazole-2-)benzyl)-1H-benzimidazole in a proper amount of a DMF solvent to obtain a mixture, stirring the mixture uniformly at room temperature, performing a volatilization process for seven days to obtain a slight yellow-green block-shaped complex monocrystal. The complex employs biological non-toxic element zinc as a metal ion, can be used for preparing antitumor drugs, can inhibit generation of esophagus cancer cells, and is free from remaining in human body and causing poisoning in human body due to metal accumulation. The complex is simple in the preparation method, is high in yield, is low in cost and is suitable for an industrial production.

The invention relates to a chonglou saponin I, namely, (25R)-Delta5(6)-alkene-spirost-3-O-{alpha-L- arabinofuranosyl (1->4)}-[alpha-L-rhamnopyranosyl (1->2)]-3-O-beta-D-glucopyranoside preparation method and an application for inhibiting angiogenesis thereof; the preparation method is composed of extracting polyphylla by using organic solvent and preparing chonglou saponin I by silica gel and reverse phase silica gel chromatography which can be used as an anti-neoplastic drug.

The invention relates to a new structure of bilactone dimer and the producing method, and the natural product selecting to human HL-60, CNE, KB, A549, BEL-7404 and Hela. It could be used to produce anti-tumor medicine.

The invention relates to artemisinin derivates as shown in a general formula I, optically active isomers and pharmaceutically acceptable salts thereof, wherein the substituents R1, R2, X and Ar have the meanings defined in the specification. The invention also relates to application of the compound shown in general formula I in the preparation of medicaments for treating and/or preventing cancer.

The invention discloses a method and a device for cultivating high-concentration photosynthetic bacteria with low illumination. The device comprises an anode chamber and a cathode chamber, wherein the anode chamber is made from a transparent material, and is separated from the cathode chamber through an ion exchange membrane; the anode chamber and the cathode chamber are respectively provided with an anode and a cathode; the anode and the cathode are connected through an external resistor; the ratio of surface area of the anode to effective capacity of the anode chamber is more than 0.06/cm, and ratio of resistance of the external resistor to effective capacity of the anode chamber is 4-40 ohm/cm3; the anode chamber of the device is a fermentation tank; photosynthetic bacteria cultivated to a logarithmic phase are inoculated to the anode chamber at a volume percentage of 1-10%, and the anode chamber is sealed and is communicated to an external circuit to cultivate the bacteria at 20-37 DEG C with illumination of 50-500lux. The method disclosed by the invention can cultivate high-concentration photosynthetic bacteria under low inoculum size and low illumination, and can generate electric energy while reducing illumination energy consumption; and the method is wide in application prospect.

The invention relates to a natural product sparganiaceae lactone B derivative as well as a preparation method and use for preparing anti-tumor drugs. The structural formula of the derivative is show in the description, wherein R is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C5-10 aryl, pyridyl, CnH2nX, OR1 or NR2R3; n is 1-6, X is vinyl, acetenyl, C5-10 aryl, azo-aryl containing 1-4 nitrogen atoms and 1-5 carbon atoms, hydroxyl, C1-4 alkoxyl, amino, N, N-biC1-4 alkyl amino, carboxyl, acylamino, sulphonylamino, C1-4 alkoxycarbonyl, cyano or nitryl; R1 is hydrogen, C1-4 alkyl, benzyl or methoxyl benzyl; and R2 and R3 are respectively hydrogen, C1-4 alkyl, benzyl, methoxyl benzyl or R2 and R3 jointly form a 4-7 membered ring with N atoms. The sparganiaceae lactone B derivative provided by the invention is used for anti-tumor drugs, and the compound provided by the invention is novel in structure, has relatively good druggability and relatively high activity of inhibiting tumor cell growth, and is simple and convenient in preparation method and easy to operate and amplify.

The invention relates to triazole derivatives of rapamycin and application. Concretely, the triazole derivatives of rapamycin comprises compounds of the following formula I, or pharmaceutically acceptable salts, solvates, isomers, esters and prodrugs thereof. In the formula I, n is 1, 2 or 3, X is carbonyl or chemical bonds, R is hydrogen or C1-C4 alkyl, R1 is hydrogen, hydroxyl, hydroxymethyl, halogens, trifluoromethyl, trifluoromethoxyl, amino, carboxyl, cyan, N-(C1-C4)alkylamino, N,N-di(C1-C4)alkylamino, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkoxylethyl, (C1-C4)alkylacyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, N,N-di(C1-C4)alkylcarbamoyl or (C1-C3)alkylenedioxyl. The compounds have excellent biological activity.

This invention relates to Ailinofen bi lactone and its medical used salt or solvate. This invention also relates its preparation method and its medical combination and medical application. The compound in this invention can in vitro prevent two kinds of human body tumor cells activity as oral epithelium cancer cell (KB) and human hepatic carcinoma cell (BEL-7404). It can be developed as anti tumor medicine application.

This invention relates to Ailinofen bi lactone and its medical used salt or solvate. This invention also relates its preparation method and its medical combination and medical application. The compound in this invention can in vitro prevent six kinds of human body tumor cells activity as human original medullary cell leukemia cell(HL-60), nasopharyngeal carcinoma cell(CNE), oral epithelium cancer cell(KB), human lung cancer cell(549), human hepatic carcinoma cell(BEL-7404) and human uterus neck cancer cell(Hela). It can be developed as anti tumor medicine application.

The invention relates to indolone-containing 4-thiazolidone derivatives shown in a general formula I as well as geometrical isomers and pharmaceutically acceptable salts of the indolone-containing 4-thiazolidone derivatives. In the formula I, substituted groups namely Ar, R2, R3, R4 and n are defined in the specification. The invention also relates to application of compounds of the general formula I in preparation of a medicine for treating and/or preventing cancer.

The invention discloses a conjugated dienes derivative and a preparation method and application of the conjugated dienes derivative as an anti-cancer drug. The structure of the conjugated dienes derivative is shown as formula I. Practice shows that a compound has obvious activity on inhibiting the growth of cancer cells; and the antitumor activity of some optimized compounds is obviously superior toprior to that of a contrast drug. The preparation of such compound is simple and easy to carry out; raw materials are easy to obtainily available; and the conjugated dienes derivative is a substance with antitumor activity and has a wide application prospect.

The invention, belonging to the technical field of medicine, relates to a compound, that is, 10-hydroxyamptothecin derivative, and its preparation method and pharmaceutical application. The compound is represented as formula 1, wherein X=-H, -R, -COR, R represents alkyl with 1-8 carbon atoms, the alkyl represents alkane, alkylene or aryl; Y=-H, -R', -COR, R' represents alkyl with 1-8 carbon atoms, and the alkyl represents alkane, alkylene or aryl. The results of anti-tumor bioactivity in vitro selection tests show that the compound disclosed herein has significant inhibiting effect on the growth activity of tumor cells, and the compound can be further used for preparing anti-tumor active medicines for treating tumors.

The invention provides a method for extracting and separating ganoderma triterpene extract by using a subcritical technology. The method comprises the following steps of: sequentially extracting and separating active ingredients, namely a ganoderma triterpene acid part and a ganoderma triterpene neutral part, in ganoderma from ganoderma sporocarp by using the subcritical water extraction technology under different pressure and temperature conditions. According to the method, different active extracts in ganoderma are efficiently and economically obtained by using the subcritical water extraction technology. The antioxidant activity of the DPPH clearance rate of the ganoderma triterpene acid part in the obtained active extract can reach 88.38%, the semi-inhibition ratio IC50 of the ganoderma triterpene neutral part to human large cell lung cancer cells H460 is 95.0 micrograms/ml, and the semi-inhibition ratio IC50 of the ganoderma triterpene neutral part to human hepatoma carcinoma cells HepG2 is 77.7 micrograms/ml.

The invention relates to a drug use of diacetyl-diphenyl-heptane to prevent and cure chronic Bone marrow-derived leukemia. Specifically, the invention relates to the drug use of 3, 5-diacetyl group-1-(3- methoxyl group-4, 5-dihydroxy phenyl)-7-(4-hydroxy-3- methoxyl group phenyl) heptane and the medicinal salt thereof in the preparation of prevention and treatment of chronic Bone marrow-derived leukemia. The compound is extracted mainly from ginger, curcuma wenyujin, zedoary and other zingiberaceae plants. Pharmacological experiments are proved that the compound has potent inhibitory effect on chronic Bone marrow-derived leukemia cell strain (K562) of human and the adriamycin-resistant strain (K562/ADR) proliferatione in vitro thereof, wherein, the value of IC50 is 34.9 plus or minus 0.6 and 50.6 plus or minus 23.5 Mum respectively.